Rua Bioscience raises ~$88K via convertible note to fund growth
What's the deal? Rua BioscienceDealroom has a profile for this one. Try Dealroom →, an NZX-listed New Zealand pharmaceutical company, has issued an unlisted NZ$150,000 (roughly $88,000) convertible note to selected wholesale investors. The note is interest-bearing, unsecured, and fully paid on issue.
The terms: It can convert into up to 6,000,000 ordinary shares at NZ$0.025 per share, or the lower price of any qualifying capital raise. Conversion happens at the company's option after 12 months, or automatically if Rua completes a raise of more than NZ$1.5 million within that period.
Why now? The board framed the note as a timely source of growth capital. It said the structure limits immediate dilution for existing shareholders while aligning lenders with Rua's long-term equity performance.
What's the endgame? Rua develops and commercialises bioscience and medicinal products, and it taps growth capital through both listed equity and structured instruments to fund expansion. If converted at the lowest price, the note would lift shares on issue from 339,441,705 to 345,441,705, leaving its 8,733,456 outstanding warrants unchanged.
The signal: At roughly $88,000, the raise sits well below typical funding rounds — in the bottom slice by size. For a company with a market cap near NZ$12.22 million, the convertible note is a modest, low-dilution bridge rather than a headline injection, reflecting how smaller listed players stretch capital between larger raises.
Read more: blog.tipranks.com
Image credit: Generated with Gemini
